Method for evaluating in-vitro hypotonic thrombolysis effect and application thereof
By mixing hypotonic saline with blood clots, the thrombolytic effect was evaluated, which solved the problem of the difficulty in eliminating vascular plaques in existing technologies and achieved an effective blood plaque dissolution effect. 0.3% sodium chloride aqueous solution was the best thrombolytic agent.
Patent Information
- Application Number
- CN202311299626.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-09
- Publication Date
- 2026-04-10
AI Technical Summary
Existing technologies are not very effective in eliminating vascular plaques, and current drug treatments are difficult to effectively dissolve vascular plaques.
Hypotonic saline was mixed with blood clots, and the thrombolytic effect was evaluated by comparing the diameter, wet weight, and dry weight of the blood clots after standing. Hypotonic saline was also used to prepare drugs for thrombolysis.
This study provides a highly operable method that can effectively assess the dissolution of blood plaques under hypotonic conditions, laying an experimental platform for novel plaque dissolution methods. The results show that a 0.3% sodium chloride aqueous solution has the best thrombolytic effect.
Abstract
Description
TECHNICAL FIELD
[0001] The embodiment of the present application relates to the technical field of biomedical engineering, in particular to an evaluation method for thrombolytic effect of in-vitro low-osmotic and application thereof. BACKGROUND
[0002] The vascular plaque is some yellowish and white blocky substances like porridge in texture embedded in the inner layer of the arterial vessel wall. Its formation is a very complex process, which has certain relationship with blood pressure, lifestyle, eating habits, age and other factors. The vascular intima (the innermost layer of the vessel wall) is damaged due to factors such as smoking, high blood pressure, high blood lipids, etc. After the damage, the entry of inflammatory cells (involved in the body's inflammatory response) and the deposition of lipid substances (the general term of fat and lipid) cause bleeding under the intima. With the extension of time, fibrosis (organ cell necrosis caused by inflammation after persistent damage to the innermost layer of the blood vessel) or calcification (hardening, calcium deposition, reduced elasticity) under the vascular intima may occur, and then the vascular plaque is formed.
[0003] The vascular plaque is the direct cause of blood vessel occlusion and even embolism. In addition to adjusting diet and changing lifestyle, the common drug treatments in the prior art include: using western medicines such as hypolipidemic drugs, anti-platelet drugs, vasodilator drugs, thrombolytic drugs and anticoagulant drugs, common drugs are aspirin, clopidogrel, atorvastatin, rosuvastatin, ezetimibe, etc.; using traditional Chinese medicines with the functions of promoting blood circulation, reducing phlegm and dredging collaterals, common ones are salvia miltiorrhiza, hawthorn, chuanxiong, red peony root, lotus leaf, cassia seed, gualou and atractylodes etc. It is found that the existing method has the problem of poor effect of eliminating the vascular plaque.
[0004] In view of this, the present application is proposed. SUMMARY
[0005] To this end, the embodiment of the present application provides an evaluation method for thrombolytic effect of in-vitro low-osmotic and application thereof.
[0006] In order to achieve the above-mentioned purpose, the embodiment of the present application provides the following technical scheme:
[0007] According to the first aspect of the embodiment of the present application, the present application provides an evaluation method for thrombolytic effect of in-vitro low-osmotic, which comprises:
[0008] providing a first blood clot;
[0009] mixing the first blood clot with low-osmotic saline, standing to obtain a second blood clot;
[0010] comparing the performance indicators of the first blood clot and the second blood clot to evaluate the thrombolytic effect.
[0011] Further, the performance indicators are the diameter, wet weight and dry weight of the blood clot.
[0012] Further, the temperature of the standing is 37℃, and the time is 14h.
[0013] According to a second aspect of the embodiments of the present application, the present application provides use of the method according to any one of the above in the preparation of a medicament for treating thrombolysis.
[0014] According to a third aspect of the embodiments of the present application, the present application provides use of the low-osmolar saline in the preparation of a medicament for treating thrombolysis.
[0015] Further, the concentration of the low-osmolar saline is 0.3%.
[0016] The embodiments of the present application have the following advantages:
[0017] The present application explores the change of blood clot dissolution under low-osmolar conditions, and lays an experimental platform for establishing a new clot dissolution method. The method provided by the present application has strong operability and good application prospect. DETAILED DESCRIPTION
[0018] The embodiments of the present application will be described in detail by the following specific examples, and those skilled in the art can easily understand other advantages and effects of the present application from the contents disclosed in the present specification. Obviously, the described embodiments are part of the embodiments of the present application, but not all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative labor fall within the scope of protection of the present application.
[0019] Example 1
[0020] Reference is made to the preparation of blood clots in the research and research of in vitro thrombus formation by Han Fu et al., and the specific process is as follows:
[0021] (1) Select healthy subjects who voluntarily participate in the test
[0022] (I) Diet: Fasting or not eating high-fat and high-protein food within 12h before blood collection.(2) Smoking and drinking: Smoking and drinking are prohibited within 12h before blood collection.(3) Medication: Do not take aspirin and other drugs that affect platelet function determination within 7d.(4) The subject needs to be in a quiet state before blood collection.
[0023] (2) Standard operation
[0024] (1) Blood must be drawn from the patient using disposable syringes and vacuum tubes, and a larger needle (size 8) should be used. The blood draw should be smooth and quick, aiming for a single successful draw; slowly inject the blood into the silicone rubber tube (artificial blood vessel) made of silicone polymer material, avoiding excessive force to prevent air bubbles from forming in the blood. (2) Add 1.6 ml of blood, seal it, and quickly place it onto the plexiglass plate of the thrombus analyzer. Turn on the instrument and adjust the liquid level; this process should be completed within 60 seconds. Maintain an indoor temperature of 22℃-25℃ and an instrument temperature of 36.5℃-37.0℃. Temperature directly affects thrombus formation and outcome. (3) The silicone tube should be cleaned with a neutral cleaning solution and gently brushed with a soft brush. Discard any tube with scratches. The cleaning solution should be changed frequently.
[0025] (3) Observation of the experimental process and measurement of thrombi
[0026] (1) Observation: After rotating for 1 minute, observe the angle formed between the blood sample and the plane. Start recording the time when the angle changes; this is the specific thrombus formation time (cTFT). The time when the angle no longer increases is the fibrin thrombus formation time (FFT). (2) Measurement: After 15 minutes, remove the silicone thrombus tube, gently pour the blood sample onto filter paper, and gently hold the thrombus head with ophthalmic forceps (the head is covered with a silicone rubber tube) to let it hang naturally. Then place it on filter paper to absorb the fresh blood on the surface of the thrombus, and measure the length of the thrombus with vernier calipers. After air-drying, weigh the wet weight of the thrombus using a precision torque balance. Then, place the thrombus specimen along with the paper in a glass container and put it in an oven (64℃, 15 minutes). Remove it and weigh the dry weight of the thrombus.
[0027] According to statistics, the length of the prepared thrombus was 5.23±0.61cm, the wet weight of the thrombus was 0.85±0.34g, and the dry weight of the thrombus was 0.68±0.27g.
[0028] Example 2
[0029] In vitro thrombolysis studies utilize the osmotic pressure gradient to achieve dissolution under the same environmental conditions such as temperature and pH. Since hypotonic dissolution avoids tissue damage caused by hypertonicity, it is an ideal choice. Currently, there are no reported methods for hypotonic plaque dissolution, either domestically or internationally. This embodiment attempts to observe the effects of various concentrations of hypotonic saline on plaque dissolution.
[0030] Research Methods: At 37°C, the thrombus prepared in Example 1 was mixed with hypotonic saline solutions of different concentrations (0.1%, 0.3%, 0.5%, and 0.7% sodium chloride aqueous solution) and allowed to stand for 8 hours. The mixture was then gently poured onto filter paper. The thrombus head was gently held with ophthalmic forceps (the tip covered with a silicone rubber tube) and allowed to hang naturally. The thrombus was then placed on filter paper to absorb the fresh blood on its surface, and the length of the thrombus was measured using calipers. After air-drying, the wet weight of the thrombus was measured using a precision torque balance. The thrombus specimen, along with the paper, was then placed in a glass container and placed in an oven (64°C, 15 min). After removal, the dry weight of the thrombus was measured. Normal physiological saline (isotonic saline solution with 0.9% sodium chloride aqueous solution) was used as a control. The results are shown in Table 1 below.
[0031] Table 1
[0032] Saline concentration Thrombus length / cm Thrombus wet weight / g Thrombus dry weight / g 0.1% 3.81±0.18 0.61±0.22 0.42±0.15 0.3% 2.24±0.48 0.32±0.24 0.19±0.05 0.5% 4.67±0.37 0.75±0.18 0.54±0.08 0.7% 4.05±0.53 0.67±0.11 0.48±0.11 0.9% 5.10±0.42 0.81±0.15 0.65±0.13
[0033] The results showed that hypotonic saline was more effective at promoting plaque dissolution than isotonic saline, and 0.3% sodium chloride aqueous solution had the best thrombolytic effect.
[0034] The settling time was investigated at the optimal saline concentration (0.3% sodium chloride aqueous solution), and the results are shown in Table 2 below.
[0035] Table 2
[0036] Resting time Thrombus length / cm Thrombus wet weight / g Thrombus dry weight / g 8h 2.24±0.48 0.32±0.24 0.19±0.05 14h 2.05±0.42 0.21±0.19 0.16±0.04 18h 2.03±0.38 0.20±0.18 0.15±0.04
[0037] The results showed that the length, wet weight, and dry weight of the thrombus continued to decrease with prolonged settling time. The aforementioned performance indicators of the thrombus after 18 hours of settling were essentially the same as those after 14 hours; therefore, the optimal settling time was 14 hours.
[0038] Example 3
[0039] Animal experiments
[0040] Healthy male Wistar rats (weighing 250±20g) were selected for the following experiment.
[0041] Thrombus preparation: Blood was collected from the right common iliac vein of rats to prepare thrombi according to the method in Example 1, and the thrombi were cut into thrombus particles with a length of about 0.5 mm for later use.
[0042] Establishment of a thrombosis model: After anesthetizing rats in each group with 10% chloral hydrate via intraperitoneal injection, four thrombus particles were injected retrogradely into the external carotid artery with a syringe, and then ICA blood flow was restored.
[0043] Animal grouping: Thrombosis model rats were randomly divided into a hypotonic saline treatment group, a urokinase treatment group, and a blank control group. The hypotonic saline treatment group received 10 ml of 0.3% sodium chloride solution intravenously, while the urokinase treatment group received 1 × 10⁻⁶ urokinase solution intravenously. 4 U / animal, while the blank control group received 10 ml of 0.9% sodium chloride aqueous solution intravenously. The injection time was approximately 20 minutes.
[0044] Examining the Willis ring and measuring the infarct size: 12 hours after thrombus injection, rats were anesthetized, decapitated, and the brains were completely removed. The Willis rings of each group were examined to observe the presence and location of the thrombus. Brain slices were placed in 2% TTC solution and incubated at 37°C for 30 minutes. The size of the infarct lesion was measured. The results are shown in Table 3 below.
[0045] Table 3
[0046] Group Infarction size / % Low-osmolar saline treatment group 21.0±5.1 Urokinase treatment group 28.4±4.3 Blank control group 36.5±5.7
[0047] The results showed that the 0.3% sodium chloride provided in this embodiment of the invention can effectively dissolve thrombi.
[0048] Although the present invention has been described in detail above with general descriptions and specific embodiments, modifications or improvements can be made to it, which will be obvious to those skilled in the art. Therefore, all such modifications or improvements made without departing from the spirit of the present invention fall within the scope of protection claimed by the present invention.
Claims
1. A method for evaluating the efficacy of in vitro hypotonic thrombolysis, characterized in that, The method includes: Provides the first blood clot; The first blood clot was mixed with hypotonic saline and allowed to stand to obtain the second blood clot. The thrombolytic effect was evaluated by comparing the performance indicators of the first and second blood clots.
2. The method for evaluating the efficacy of in vitro hypotonic thrombolysis according to claim 1, characterized in that, The performance indicators are the diameter, wet weight, and dry weight of the blood clot.
3. The method for evaluating the efficacy of in vitro hypotonic thrombolysis according to claim 1, characterized in that, The settling temperature was 37°C, and the settling time was 14 hours.
4. Use of the method according to any one of claims 1-3 in the preparation of a medicament for treating thrombolysis.
5. Application of hypotonic saline in the preparation of drugs for thrombolysis.
6. The application according to claim 5, characterized in that, The concentration of the hypotonic saline solution is 0.3%.
